Walleye Capital LLC reduced its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 46.0% during the 1st quarter, HoldingsChannel reports. The firm owned 10,645 shares of the medical equipment provider’s stock after selling 9,063 shares during the quarter. Walleye Capital LLC’s holdings in Lantheus were worth $589,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. City State Bank purchased a new position in Lantheus during the fourth quarter worth approximately $83,000. Fairfield Bush & CO. purchased a new position in shares of Lantheus during the 1st quarter worth $177,000. FORA Capital LLC acquired a new position in shares of Lantheus during the 1st quarter valued at about $202,000. Mackenzie Financial Corp purchased a new stake in shares of Lantheus in the first quarter valued at about $212,000. Finally, GSA Capital Partners LLP acquired a new stake in Lantheus during the first quarter worth about $216,000. 98.14% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
LNTH has been the topic of several recent analyst reports. B. Riley reiterated a “buy” rating on shares of Lantheus in a report on Thursday, August 25th. SVB Leerink upped their price objective on Lantheus from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Friday, August 5th.
Insiders Place Their Bets
Lantheus Stock Down 3.8 %
Shares of LNTH opened at $73.20 on Thursday. The company’s 50-day moving average price is $78.47 and its 200 day moving average price is $67.19. Lantheus Holdings, Inc. has a 12-month low of $22.20 and a 12-month high of $87.47. The company has a current ratio of 1.85, a quick ratio of 1.69 and a debt-to-equity ratio of 0.27. The firm has a market cap of $5.03 billion, a P/E ratio of 170.23 and a beta of 0.77.
Lantheus (NASDAQ:LNTH – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The medical equipment provider reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.17. The business had revenue of $223.80 million for the quarter, compared to the consensus estimate of $204.51 million. Lantheus had a net margin of 4.88% and a return on equity of 28.88%. The business’s revenue was up 121.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.11 EPS. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 3.29 earnings per share for the current year.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- General Mills: Superior Returns With Less Volatility
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.